Cerebral and lung effects of a new generation synthetic surfactant with SP‐B and SP‐C analogs in preterm lambs

BACKGROUND Though natural surfactants (SF) are clinically superior to protein‐free synthetic preparations, CHF‐5633, a synthetic SF containing SP‐B and SP‐C analog peptides is a potential alternative to natural SF for treating neonatal respiratory distress syndrome (RDS). Nevertheless, information i...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric pulmonology 2017-07, Vol.52 (7), p.929-938
Main Authors: Rey‐Santano, Carmen, Mielgo, Victoria E., Murgia, Xabier, Gomez‐Solaetxe, Miguel Angel, Salomone, Fabrizio, Bianco, Federico, Pelizzi, Nicola, Loureiro, Begoña, López de Heredia y Goya, Jon
Format: Article
Language:English
Subjects:
Animals
Animals, Newborn
Biological Products - therapeutic use
Blood Gas Analysis
brain
Brain - drug effects
Brain - pathology
Brain - physiology
Carotid arteries
Cerebrovascular Circulation - drug effects
Female
Hemodynamics
histology
Lung - drug effects
Lung - pathology
Lung - physiology
Male
neonate
Peptide Fragments - therapeutic use
Phosphatidylcholines - therapeutic use
Phospholipids - therapeutic use
Pulmonary Gas Exchange - drug effects
Pulmonary Surfactant-Associated Protein B - therapeutic use
Pulmonary Surfactant-Associated Protein C - therapeutic use
Pulmonary Surfactants - therapeutic use
Respiratory distress syndrome
Respiratory Distress Syndrome, Newborn - drug therapy
Respiratory Distress Syndrome, Newborn - pathology
Respiratory Distress Syndrome, Newborn - physiopathology
Sheep
Surfactants
Swine
synthetic surfactant
Traumatic brain injury
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Though natural surfactants (SF) are clinically superior to protein‐free synthetic preparations, CHF‐5633, a synthetic SF containing SP‐B and SP‐C analog peptides is a potential alternative to natural SF for treating neonatal respiratory distress syndrome (RDS). Nevertheless, information is lacking regarding the safety of this new treatment for the neonatal brain. We sought to compare the cerebral and pulmonary effects of this new synthetic surfactant (CHF5633) with those of natural porcine surfactant (Cursosurf) in premature lambs with RDS. METHODS Twenty‐one preterm lambs were randomly assigned to receive CHF5633, Curosurf, or no treatment (control). Pulmonary (gas exchange, lung mechanics) and cerebral (carotid artery blood flow, cerebral oxygen metabolism) effects were measured every 30 min for 6 h. Pulmonary and cerebral histological analysis were also performed. RESULTS After delivery, lambs developed severe RDS (FIO2:1, pH  70 mmHg, PaO2 
ISSN:8755-6863
1099-0496
DOI:10.1002/ppul.23685